Chemed (CHE) Competitors

Chemed (NYSE:CHE) and Amedisys (NASDAQ:AMED) are both mid-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their community ranking, earnings, institutional ownership, risk, analyst recommendations, media sentiment, profitability, valuation and dividends.

Do insiders and institutionals hold more shares of CHE or AMED?

95.9% of Chemed shares are owned by institutional investors. Comparatively, 94.4% of Amedisys shares are owned by institutional investors. 3.3% of Chemed shares are owned by insiders. Comparatively, 1.8% of Amedisys shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Does the media refer more to CHE or AMED?

In the previous week, Amedisys had 5 more articles in the media than Chemed. MarketBeat recorded 12 mentions for Amedisys and 7 mentions for Chemed. Amedisys' average media sentiment score of 0.65 beat Chemed's score of 0.50 indicating that Amedisys is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Chemed	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Amedisys	4 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Does the MarketBeat Community prefer CHE or AMED?

Amedisys received 166 more outperform votes than Chemed when rated by MarketBeat users. However, 63.39% of users gave Chemed an outperform vote while only 58.93% of users gave Amedisys an outperform vote.

Company	Underperform	Outperform
Chemed	Outperform Votes 329 63.39%	Underperform Votes 190 36.61%
Amedisys	Outperform Votes 495 58.93%	Underperform Votes 345 41.07%

Which has more volatility & risk, CHE or AMED?

Chemed has a beta of 0.46, indicating that its stock price is 54% less volatile than the S&P 500. Comparatively, Amedisys has a beta of 0.84, indicating that its stock price is 16% less volatile than the S&P 500.

Do analysts rate CHE or AMED?

Chemed presently has a consensus price target of $681.00, suggesting a potential upside of 21.25%. Amedisys has a consensus price target of $97.50, suggesting a potential upside of 5.89%. Given Chemed's stronger consensus rating and higher probable upside, analysts clearly believe Chemed is more favorable than Amedisys.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Chemed	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00
Amedisys	0 Sell rating(s)	7 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.13

Which has higher valuation & earnings, CHE or AMED?

Chemed has higher revenue and earnings than Amedisys. Amedisys is trading at a lower price-to-earnings ratio than Chemed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Chemed	$2.26B	3.76	$272.51M	$18.58	30.23
Amedisys	$2.24B	1.35	-$9.75M	-$0.64	-143.87

Is CHE or AMED more profitable?

Chemed has a net margin of 12.36% compared to Amedisys' net margin of -0.91%. Chemed's return on equity of 30.52% beat Amedisys' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Chemed	12.36%	30.52%	20.13%
Amedisys	-0.91%	12.85%	6.95%

Summary

Chemed beats Amedisys on 14 of the 18 factors compared between the two stocks.